title: Low incidence of post-thrombotic syndrome in patients treated with new oral anticoagulants and percutaneous endovenous intervention for lower extremity deep venous thrombosis.
abstract: Post-thrombotic syndrome (PTS) is a common complication of deep venous thrombosis (DVT) of the iliofemoral venous system leading to significant morbidity and high health care costs. It has been recently shown that percutaneous endovenous intervention (PEVI) can effectively reduce the incidence of PTS. The role of new oral anticoagulants (NOACs) in combination with PEVI in the reduction of PTS has not been previously studied. This report sought to evaluate the role of PEVI plus NOACs in the reduction of PTS in acute symptomatic femoropopliteal and iliac DVT. We studied 127 patients with acute lower extremity DVT who had undergone PEVI plus administration of NOACs. All had received a minimum of 3 months of anticoagulation with a NOAC following PEVI. The mean follow-up was 22±5 months. The patients were evaluated for development of PTS, bleeding, recurrent venous thromboembolism (VTE), duration of hospitalization and mortality. There was no in-hospital bleeding. The mean duration of hospitalization was 46±9 hours. DVT occurred in two patients who had been later switched to warfarin. There were four non-VTE-related deaths. PTS developed in five patients (3%), two of whom were those who had been switched to warfarin. Their mean Villalta score was 6.2±0.9. We conclude that the combination of PEVI plus NOAC and low dose aspirin is associated with a very low rate of PTS with the severity being only mild. This approach leads to very low rates of bleeding and recurrent VTE and promotes early discharge.
authors.affiliation: Arizona Cardiovascular Consultants & Vein Clinic, Mesa, AZ, USA A.T. Still University, Mesa, AZ, USA seyedmohsensharifi@yahoo.com.
authors.forename: Mohsen
authors.initials: M
authors.lastname: Sharifi
authors.affiliation: A.T. Still University, Mesa, AZ, USA.
authors.forename: Wilbur
authors.initials: W
authors.lastname: Freeman
authors.affiliation: A.T. Still University, Mesa, AZ, USA.
authors.forename: Curt
authors.initials: C
authors.lastname: Bay
authors.affiliation: Arizona Cardiovascular Consultants & Vein Clinic, Mesa, AZ, USA.
authors.forename: Mirali
authors.initials: M
authors.lastname: Sharifi
authors.affiliation: A.T. Still University, Mesa, AZ, USA.
authors.forename: Frederic
authors.initials: F
authors.lastname: Schwartz
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D015994:Incidence; D035002:Lower Extremity / Q000098:blood supply / Q000503:physiopathology*; D008297:Male; D054070:Postthrombotic Syndrome / Q000453:epidemiology*; D012307:Risk Factors; D013997:Time Factors; D020246:Venous Thrombosis / Q000188:drug therapy* / Q000453:epidemiology*; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D014859:Warfarin
keywords: deep vein thrombosis; endovenous intervention; new oral anticoagulants; post-thrombotic syndrome